A Nutritional Intervention for Diabetic Neuropathy (WCCR-DN2)
1 other identifier
interventional
20
1 country
1
Brief Summary
The purpose of this study is to assess whether, in individuals with diabetic neuropathy, a low-fat, vegan diet in combination with a vitamin B12 supplement improves pain, sensation and other subjective symptoms, more effectively than a vitamin B12 supplement with no diet changes. The principal measure is pain as measured by the following assessment tools: Michigan Neuropathy Screening Instrument, Norfolk Quality of Life Questionnaire, Neuropathy Impairment Score - Lower Limbs, Neuropathy Total Symptom Score, Neuropathy Pain Scale, McGill Pain Questionnaire and Global Impression Scale. The study duration is 20 weeks. This study also examines the effects of a low-fat, vegan diet on mood, using the Center for Epidemiologic Studies Depression Scale-Revised, and the Beck Depression Inventory.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2013
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2013
CompletedFirst Submitted
Initial submission to the registry
September 26, 2013
CompletedFirst Posted
Study publicly available on registry
October 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2015
CompletedApril 27, 2015
April 1, 2015
1.5 years
September 26, 2013
April 24, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Pain
Pain will be measured follow the baseline and 20 week score using the following assessment tools: Michigan Neuropathy Screening Instrument Norfolk Quality of Life Questionnaire Neuropathy Impairment Score - Lower Limbs Neuropathy Total Symptom Score 6 Neuropathy Pain Scale McGill Pain Questionnaire Global Impression Scale
20 weeks
Secondary Outcomes (5)
Sensation
20 Weeks
Disease activity
20 Weeks
Glycemic control
20 Weeks
Mood
20 Weeks
Quality of life
20 Weeks
Other Outcomes (1)
Acceptability of vegan diet
20 Weeks
Study Arms (2)
Vegan diet and vitamin B12 supplement
EXPERIMENTALThe diet/supplement group will be asked to follow a low-fat, vegan diet for 20 weeks, and take a vitamin B12 supplement daily.
Vitamin B12 supplement
ACTIVE COMPARATORThe supplement group will be asked to take a daily vitamin B12 supplement, and to make no changes to their current diet.
Interventions
A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
Eligibility Criteria
You may qualify if:
- Men and women age 18 - 65 years old
- A diagnosis of type 2 diabetes
- A diagnosis of diabetic neuropathy for at least 6 months or symptoms of diabetic neuropathy for at least 6 months
- Score of greater than 2 on the Michigan Neuropathy Screening Instrument
- Score of greater than 6on the Norfolk Quality of Life Questionnaire
- Score of greater than 2 on the Neuropathy Impairment Score for Lower Limbs (NIS-LL)
- Score of greater than 1 on the Neuropathy Total Symptom Score 6 (NTSS-6)
You may not qualify if:
- Vitamin B12 deficiency
- Alcohol consumption of more than 2 drinks per day or the equivalent, episodic increased drinking (e.g., more than 2 drinks per day on weekends), or a history of alcohol abuse or dependency followed by any current use
- Pregnancy
- Unstable medical or psychiatric illness
- Likely to be disruptive in group sessions (as determined by research staff)
- Already following a low-fat, vegan diet
- Lack of English fluency
- Inability to maintain current medication regimen
- Inability or unwillingness to participate in all components of the study
- Sensitivity to lidocaine or epinephrine (or their preservatives)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Physicians Committee for Responsible Medicine
Washington D.C., District of Columbia, 20016, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Neal Barnard, MD
Physicians Committee for Responsible Medicine
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 26, 2013
First Posted
October 1, 2013
Study Start
September 1, 2013
Primary Completion
March 1, 2015
Study Completion
March 1, 2015
Last Updated
April 27, 2015
Record last verified: 2015-04